Education
About Us
Working with TipRanks
Follow Us
Fortrea Holdings Inc. (FTRE)
NASDAQ:FTRE
FTRE Stock Chart & Stats
$14.88
-$0.82(-4.27%)
At close: 4:00 PM EST
$14.88
-$0.82(-4.27%)
Day’s Range― - ―
52-Week Range$3.97 - $18.67
Previous CloseN/A
Volume188.47K
Average Volume (3M)1.27M
Market Cap
$1.37B
Enterprise Value$2.43B
Total Cash (Recent Filing)$131.30M
Total Debt (Recent Filing)$1.19B
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Feb 26, 2026EPS Estimate
0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.12
Shares Outstanding92,400,000
10 Day Avg. Volume1,475,439
30 Day Avg. Volume1,274,958
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.23
Price to Sales (P/S)0.62
P/FCF Ratio7.03
Enterprise Value/Market Cap1.77
Enterprise Value/Revenue0.88
Enterprise Value/Gross Profit5.12
Enterprise Value/Ebitda-2.85
Forecast
1Y Price Target
$16.17Price Target Upside8.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)0.78
Revenue Forecast (FY)$2.73B
Bulls Say, Bears Say
Bulls Say
Biopharma Cycle And FundingAn accelerating biopharma cycle and stronger biotech funding can lift demand for the company's services and support revenue growth.
Leadership And ExecutionNew leadership under Anshul Thakral has increased focus and execution, which could accelerate strategic initiatives and improve company performance.
Margin Expansion And Cost DisciplineOngoing cost-savings, SG&A reductions, and gross margin improvements from streamlining initiatives can expand operating margins toward peer levels.
Bears Say
Compensation Structure And Competitive PricingReintroduction of variable compensation, together with a competitive pricing environment for FSP services, may act as a headwind to margins.
Cyclical Exposure And Drug-pricing RiskExposure to a cyclical recovery in biopharma spending creates the risk that demand could fade and renewed drug-pricing pressure could compress revenue.
Weak B2B Demand And Passthrough PressuresSustained weakness in B2B demand and passthrough cost pressures can contract top-line growth and tighten margins.
Fortrea Holdings Inc. News
FTRE FAQ
What was Fortrea Holdings Inc.’s price range in the past 12 months?
Fortrea Holdings Inc. lowest stock price was $3.97 and its highest was $18.67 in the past 12 months.
What is Fortrea Holdings Inc.’s market cap?
Fortrea Holdings Inc.’s market cap is $1.37B.
When is Fortrea Holdings Inc.’s upcoming earnings report date?
Fortrea Holdings Inc.’s upcoming earnings report date is Feb 26, 2026 which is in 14 days.
How were Fortrea Holdings Inc.’s earnings last quarter?
Fortrea Holdings Inc. released its earnings results on Nov 05, 2025. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.16 by -$0.04.
Is Fortrea Holdings Inc. overvalued?
According to Wall Street analysts Fortrea Holdings Inc.’s price is currently Undervalued.
Does Fortrea Holdings Inc. pay dividends?
Fortrea Holdings Inc. does not currently pay dividends.
What is Fortrea Holdings Inc.’s EPS estimate?
Fortrea Holdings Inc.’s EPS estimate is 0.17.
How many shares outstanding does Fortrea Holdings Inc. have?
Fortrea Holdings Inc. has 92,400,000 shares outstanding.
What happened to Fortrea Holdings Inc.’s price movement after its last earnings report?
Fortrea Holdings Inc. reported an EPS of $0.12 in its last earnings report, missing expectations of $0.16. Following the earnings report the stock price went up 23.196%.
Which hedge fund is a major shareholder of Fortrea Holdings Inc.?
Currently, no hedge funds are holding shares in FTRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fortrea Holdings Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.17 (8.65% Upside)
$16.17 (8.65% Upside)
Blogger Sentiment
Bullish
FTRE Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.6%
Last 30 Days ▼ 16.2%
Last 30 Days ▼ 16.2%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.20%
12-Months-Change
Fundamentals
Return on Equity
-98.13%
Trailing 12-Months
Asset Growth
-25.15%
Trailing 12-Months
Company Description
Fortrea Holdings Inc.
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
FTRE Company Deck
FTRE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a mix of positive developments such as revenue growth, improved book-to-bill ratio, and strong cash position, alongside challenges like decreased adjusted EBITDA and a competitive FSP pricing environment. The positive aspects, including strategic innovations and high client satisfaction, generally outweighed the negatives.View all FTRE earnings summariesFTRE Stock 12 Month Forecast
Average Price Target
$16.17
▲(8.65% Upside)
Technical Analysis
Nektar Therapeutics
―
Fulcrum Therapeutics
―
Compass Therapeutics
―
Erasca
―
Aura Biosciences Inc
―
Ownership Overview
0.52% Insiders
19.12% Mutual Funds
0.46% Other Institutional Investors
46.43% Public Companies and
Individual Investors